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ABSTRACT 
Neuropathy a disease of nerve is the common cause of pain in modern world. Chronic neuropathic pain is the mo st disturbing 
symptom of lesions in the peripheral nervous system that can be of many forms. Peripheral neuropathy is often distressing may  produce 
disabilities or even found to be fatal. There are several things that cause neuropathies, understanding of the different types of neuropathies as 
well as their causes, symptoms, treatment options and prognoses is important for management of the painful disease. Symptoms of different 
painful neuropathies can be similar that sometimes diagnosing the exact type becomes a long and challenging process. This review explores 
various aspects of neuropathy and explains how health care practitioners should approach the assessment and diagnosis for management and 
pharmacotherapy of neuropathic pain. 
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INTRODUCTION 
The term neuropathy is short for peripheral neuropathy, 
meaning nerve damage in the peripheral nervous system and so 
affects nerves outside of the brain and spinal cord - it does not 
include nerve damage in the central nervous system. The peripheral 
nervous system is divided into the somatic and the autonomic 
nervous systems (ANS). Somatic motor nerve fibers control skeletal 
muscle function, while the sensory fibers mediate cutaneous and 
some deep sensations. The autonomic sensory and motor nerve 
fibers control most aspects of cardiovascular, gastrointestinal, 
bladder, and sexual functions. 
Neuropathy Known as Polyneuropathy in which it 
typically affects more than one nerve, simply as nerve pain a 
complication found in a number of different underlying conditions. 
Doctors call idiopathic neuropathy when the underlying cause has 
not been diagnosed,. Neuropathic pain syndromes exhibit both 
positive and negative sensory symptoms and signs. Nonsensory 
neurological symptoms and signs depend on the underplaying cause 
and may independently contribute to pain and disability. According 
to International Association for the Study of Pain, neuropathic pain 
is the pain initiated or caused by a primary lesion or dysfunction in 
the peripheral nervous system [1, 2]. 
DIAGNOSIS: 
The diagnosis of neuropathic pain is based on a medical 
history, review of systems, physical and neurological examination, 
and appropriate laboratory studies including blood and serologic 
tests, magnetic resonance imaging and electrophysiological studies, 
nerve biopsy or skin biopsy is required for some cases. Symptoms of 
different painful neuropathies can be similar therefore sometimes 
diagnosing the exact type becomes a long and challenging process. 
The evaluation of pain and other symptoms is required for the 
diagnosis and on the basis of that therapy is decided. Neuropathic 
pain is due to the disease or injury to the peripheral nervous 
system; clinically neuropathic pain includes positive as well as 
negative sensory symptoms and signs however motor signs and 
symptoms are often present [3]. 
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Assessment of pain: 
A difference between stimulus-evoked pain and 
spontaneous (stimulus-independent) pain should be recognized 
which may have different underlying mechanisms. Spontaneous 
pain can be either constant or intermittent even paroxysmal and 
most patients describe having both type of pain like constant 
“burning” pain plus intermittent pain that is “shooting” or “electric 
shock–like”. Spontaneous paresthesias and dysesthesias in addition 
exist as abnormal sensations, including crawling, numbness, itching, 
and tingling. It is important to assess the intensity, quality, and 
duration of spontaneous pain and abnormal sensations while 
investigating patient’s history [4]. 
Common neurological examination tools, including a 
cotton wisp, a foam brush, a tuning fork, and cold and warm water 
filled tubes, can be used to mimic everyday environmental stimuli 
like the gentle touch and pressure of clothing, wind, riding in a bus, 
and hot and cold temperatures evokes pain. Pain intensity can be 
rated with any of several reliable and validated verbal, numerical, or 
visual analog scales. Patients rate their pain using some type of 
progressive scale depending on perception of “no pain” to “worst 
possible pain” [5]. Unusual abnormal sensations associated with 
neuropathic pain can be assessed with measures of pain quality 
using Neuropathic Pain Scale and Neuropathic Pain Questionnaire 
[6]. Various measures of physical and emotional function can also be 
used to evaluate a patient’s response to treatment because chronic 
pain has a significant negative effect on quality of life. Assessment of 
psychological additional disorders like depression or anxiety, sleep 
disturbance, work-related issues, treatment expectations, 
rehabilitative needs, and the availability of social support from 
family and friends should be important [7, 8]. 
Altered sensation, pain, weakness, or autonomic 
symptoms were seen for patients with peripheral neuropathy. The 
clinical features vary widely and may resemble myelopathy, 
radiculopathy, muscle disease, or even hyperventilation. The 
symptoms usually begin in the toes before the fingers and spread 
proximally. The classic picture of advanced polyneuropathy with 
distal wasting and weakness, absent tendon reflexes, and glove and 
stocking sensory loss should be easy to recognize. The clinical 
features allow acute symmetrical peripheral neuropathy, chronic 
symmetrical peripheral neuropathy, and multiple mononeuropathy 
to be distinguished, each with a different differential diagnosis. 
Additional studies are required as there is no single 
diagnostic test for neuropathic pain or pain in general can confirm 
or exclude underlying causes and suggest disease specific 
treatments like for diabetes mellitus in patients with painful 
neuropathy or spinal disorders in patients with radiculopathy. 
Nerve conduction velocity tests and electromyography provide 
information about large myelinated peripheral nerve function that 
will not test smaller myelinated or unmyelinated nerve fibers 
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carrying pain and temperature information. Quantitative thermal 
sensory testing depends on the patient’s psychophysical ability to 
differentiate between fine changes in thermal stimuli; it requires 
specialized equipment and training so not widely used. 
There is no single diagnostic test for neuropathic pain or 
pain in general. Ancillary studies can confirm or exclude underlying 
causes and suggest disease specific treatments, such as for diabetes 
mellitus in patients with painful neuropathy or spinal disorders in 
patients with radiculopathy. To assess peripheral nerve function, 
nerve conduction velocity tests and electromyography provide 
information about large myelinated peripheral nerve function but 
do not test smaller myelinated or unmyelinated nerve fibers 
carrying pain and temperature information. Quantitative thermal 
sensory testing relies on the patient’s psychophysical ability to 
discriminate between fine changes in thermal stimuli; it is not 
widely used because it requires specialized equipment and training. 
Anatomical integrity of thermonociceptive sensory-processing 
regions can be made by magnetic resonance imaging (MRI). 
 
Table No. 1: Types of peripheral neuropathic pain 
Acute and chronic inflammatory demyelinating Nutritional deficiency–related neuropathies 
Polyradiculoneuropathy Painful diabetic neuropathy 
Alcoholic polyneuropathy Phantom limb pain 
Chemotherapy - induced polyneuropathy Postherpetic neuralgia 
Complex regional pain syndrome Postradiation plexopathy 
Entrapment neuropathies Radiculopathy 
(cervical, thoracic, or lumbosacral) 
HIV sensory neuropathy Toxic exposure–related neuropathies 
Iatrogenic neuralgias Tic douloureux (trigeminal neuralgia) 
Idiopathic sensory neuropathy Posttraumatic neuralgias 
Nerve compression or infiltration by tumor  
Table No. 2: Peripheral Neuropathy 
Acute Symmetrical Peripheral Neuropathy Chronic Symmetrical Peripheral Neuropathy 
Polyneuropathy  Multiple Mononeuropathy 
 
Acute symmetrical peripheral neuropathy: 
Acute symmetrical peripheral neuropathy is rare but 
important because the commonest cause is Guillain-Barré 
syndrome, which can be fatal. Common early symptoms are distal 
paraesthesiae and proximal or distal weakness occurring one to two 
weeks after a respiratory or gastrointestinal infection. Traditionally, 
the reflexes are absent, but their retention during the first hours of 
the illness has led many patients to be dismissed as “hysterical.” 
Once a patient loses the ability to walk and develops facial and 
bulbar weakness the diagnosis becomes obvious. The rapid 
progression of sensory or motor deficit requires emergency 
investigation. Patients usually have to be admitted to hospital 
because of the danger of respiratory failure. Early treatment should 
stop the pathological process before axonal dysfunction becomes 
irreversible. 
Guillain-Barré syndrome is usually due to acute 
inflammatory demyelinating polyradiculoneuropathy caused by an 
autoimmune response directed against the Schwann cells or myelin. 
Some cases are due to acute axonal neuropathy, in which glycolipid 
in the axolemma is targeted. In both forms, treatment with 
intravenous immunoglobulin hastens recovery and reduces the long 
term disability and is more convenient than plasma exchange. A 
recent trial suggests that combination treatment with steroids is 
more effective than intravenous immunoglobulin alone, but the full 
results are awaited. 
 
Table No. 3: Causes of acute sever generalized peripheral neuropathy 
Reason Nerves affected 
Guillain-Barré syndrome Predominantly Motor & Mixed 
Vasculitis Mixed 
Diabetes mellitus Predominantly Sensory & Mixed 
Porphyria Predominantly Motor 
Diphtheria Mixed 
Paraneoplastic neuropathy Predominantly Sensory &Mixed 
Acute idiopathic sensory Neuronopathy Predominantly Sensory 
Critical illness Predominantly Motor & Mixed 
Drugs Eg. nitrofurantoin, vincristine, cisplatin, 
and reverse transcriptase inhibitors. 
Predominantly Sensory & Mixed 
 
Multiple mononeuropathy: 
Acute multiple mononeuropathy is also a neurological 
emergency because the commonest cause is vasculitis. Prompt 
treatment with steroids may prevent further irreversible nerve 
damage. If multiple mononeuropathy develops in a patient with an 
established connective tissue disorder (such as rheumatoid arthritis, 
systemic lupus erythematosus, polyarteritis nodosa, or 
Churg-Strauss syndrome) it is reasonable to conclude that vasculitis 
is the cause. Steroids are the main treatment, with 
cyclophosphamide being added depending on the severity and 
general medical condition. 
Sometimes peripheral neuropathy is the presenting or 
sole feature of vasculitis. In this case, vasculitis can be diagnosed 
only by nerve biopsy. In addition, recent biopsy studies indicate that 
diabetic amyotrophy is due to microvasculitis in the lumbosacral 
plexus. It presents acutely with pain, weakness, and then wasting in 
one or both quadriceps muscles [9-11]. 
Vasculitis: 
1. Primary systemic vasculitis 
 Polyarteritis nodosa 
 Churg-Strauss syndrome (vasculitis with blood eosinophilia and 
asthma) 
2. Systemic vasculitis associated with connective tissue diseases 
 Rheumatoid arthritis 
 Sjögren's syndrome 
3. Vasculitis confined to peripheral nerves 
Other causes: 
1. Sarcoidosis 
2. Lymphoma 
3. Carcinoma 
4. Amyloid 
Multiple compression palsies: 
1. Associated with metabolic or toxic neuropathy 
2. Hereditary neuropathy with liability to pressure palsies 
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Chronic symmetrical peripheral neuropathy: 
Most peripheral neuropathies are chronic and usually 
develop over several months. Diagnosis of the underlying cause may 
require three stages of investigation. Any history of a general 
medical disorder could be relevant. Patients should always be asked 
about alcohol consumption, toxin exposure (insecticides, solvents), 
and drugs. They should also have a full examination, including 
breasts and genitalia, to exclude underlying carcinoma. 
The commonest causes of neuropathy can be identified 
from the history, examination, and simple investigations called the 
complete neurological exam and workup. A thorough physical and 
neurological examination is useful to determine the non neuropathic 
cause to the patient’s pain, most commonly musculoskeletal, 
inflammatory, myofascial, and psychological processes [3]. 
Stage 1 investigation: Physical Examination: 
Patients are instructed to carefully describe their 
symptoms and rate the severity of their abnormal sensations. 
Patients are some time confused by the complexity of their sensory 
pain experiences; they often have trouble in identifying and 
describing the unusual nature of their symptoms, also the fear that 
they will not be believed. 
When specific stimuli in the standard neurological 
sensory examination are applied first to the unaffected area and 
then to the area affected by pain, patients should be instructed to 
first respond in simple terms that is, whether the stimulus applied 
to the painful area causes the same sensation as in the unaffected 
area or whether it is less or more intense before describing their 
perception of the quality of the stimulus. For example, pin prick may 
be more painful (hyperalgesia) but less sharp because of the 
underlying sensory deficit. 
The term allodyniais is used for pain in response to a 
normally nonnoxious stimulus. Lightly rubbing or brushing the skin 
with a cotton swab or brush dynamic mechanical allodynia can be 
elicited where as static mechanical allodynia can be provoked by 
blunt pressure with a finger, and thermal allodynia can be assessed 
with a warm or cool tuning fork. An increased sensation of pain in 
response to a normally painful stimulus is termed hyperalgesia, 
which can be assessed using painful thermal (cold or heat) or 
punctate (eg, pin prick) stimuli. Painful summation and hyperpathia 
to repeated stimuli, especially when the initial sensation is reduced, 
is important evidence of abnormal sensory processing. Non sensory 
neurological and musculoskeletal symptoms can also contribute 
strongly to overall disability. Motor system symptoms and signs 
include weakness, fatigability, hypotonia, tremor, dystonia, 
spasticity, ataxia, apraxia, and motor neglect. Other musculoskeletal 
symptoms and signs include decreased range of motion, stiffness of 
joints, spontaneous muscle spasms, localized muscle tenderness, 
and myofascial trigger points. 
Sometimes the neuropathy is predominantly sensory and 
subacute with ataxia that is worse in the dark because of loss of 
large fiber function and postural sensation. This pattern is produced 
by some drugs (such as cisplatin), an underlying neoplasm, Sjögren's 
syndrome, or idiopathic sensory neuronopathy. If other members of 
the family have similar symptoms, pes cavus, or claw toes, the 
patient may have hereditary motor and sensory neuropathy or 
Charcot Marie-Tooth disease, which is usually autosomal dominant. 
Difficulty with walking in childhood also suggests a hereditary 
neuropathy. If patients have a clear cause for their neuropathy and a 
typical clinical picture, treatment for instance, of diabetes mellitus 
or alcohol misuse can be started without further investigation [12]. 
First stage investigations: Some of the investigations through lab 
tests are advised to find out the cause of the neuropathy. This 
includes tests to check for vitamin deficiencies, immune responses, 
blood sugar levels or the presence of any toxins or infections. 
Stage 1: 
 Urine: Glucose, protein 
 Haematology: Full blood count, erythrocyte sedimentation rate, 
vitamin B-12, folate 
 Biochemistry: Fasting blood glucose concentration, renal 
function, liver function, thyroid stimulating hormone 
Second stage investigations: If the cause of the neuropathy is not 
clear from the stage 1 investigations or is atypical, the patient 
should be referred to a neurologist. The most important stage 2 
investigation is neurophysiological testing. About 80% of 
symmetrical peripheral neuropathies are axonal and are due to 
gradual dying back of the axons. In the remaining 20% 
(demyelinating neuropathies) most of the damage is to the myelin, 
although axonal degeneration often occurs as the disease advances. 
The other second stage investigations are simple outpatient tests for 
the commonest causes of peripheral neuropathy. 
Electromyography (EMG) electronically studies that 
measures and records muscle activity. This tells about the location 
of any muscle, nerve or neuromuscular junction damage as well as 
its cause. A nerve conduction study to find out damage in the 
peripheral nervous system by measuring the efficiency and speed of 
electrical signals of the nerves indicates any abnormality of the 
nerves. An EMG and nerve conduction studies usually are 
simultaneously performed to get accurate diagnosis. Magnetic 
resonance imaging (MRI) may be performed to exclude any other 
causes of the neuropathy, like trauma or impingement. A spinal tap 
lumbar puncture may be done for the presence of protein or 
something else in the cerebrospinal fluid that can indicate the cause 
of the neuropathy. 
Stage 2: 
 Neurophysiological tests: Assessment of distal and proximal 
nerve stimulation 
 Biochemistry: Serum protein electrophoresis, serum 
angiotensin converting enzyme 
 Immunology: Antinuclear factor, antiextractable nuclear 
antigen antibodies (anti-Ro, anti-La), antineutrophil 
cytoplasmic antigen antibodies 
 Other: Chest radiography 
Third stage investigation: When the diagnosis cannot be made in 
any other way biopsy should be done in a specialist centre, there 
specimens are usually taken from the sural nerve after giving local 
anaesthetic. Nerve biopsy or muscle biopsy option should be used 
only on patients with distressing neuropathy to provide useful 
treatment in which small piece of nerve or muscle may be taken in 
order to look for the cause of the damage [13]. These tests are only 
done if some very specific conditions are suspected or to completely 
rule out a specific condition. The choice of third stage investigation 
will depend on whether neurophysiological testing has shown the 
neuropathy to be demyelinating or axonal 
Demyelinating neuropathy: 
The causes of demyelinating neuropathy are limited. If 
the slowing of nerve conduction affects all nerves roughly equally 
the diagnosis is likely to be the demyelinating form of 
Charcot-Marie-Tooth disease (type 1). Seventy per cent of such 
patients have a duplication of the gene for a 22 kDa peripheral nerve 
myelin protein on chromosome 17. The duplication causes over 
expression of the protein. Genetic counseling and prenatal diagnosis 
may be suggested. 
About 10% of patients with a demyelinating neuropathy 
have a serum paraprotein. Although occasionally associated with a 
solitary plasmacytoma, the paraprotein is usually benign. The 
commonest syndrome is a slowly progressive predominantly 
sensory neuropathy with an IgMêparaprotein. The paraprotein is an 
autoantibody directed against the carbohydrate antibody is directly 
responsible for the neuropathy. 
Chronic inflammatory demyelinating 
polyradiculoneuropathy is the commonest form of acquired 
demyelinating neuropathyin which Protein concentrations in the 
cerebrospinal fluid found to be increased and affects about 2 per 
100000 of the population. The patients show a proximal as well as 
distal pattern of weakness, predominantly motor and the condition 
may be relapsing and remitting. It is thought to be an autoimmune 
disease because of the inflammation in the nerves and response to 
immunotherapy. There is no diagnostic immunological test, but 
antibodies to the 28 kDa P0 myelin glycoprotein were identified in 
about a quarter of cases in a recent series and have been shown to 
induce experimental demyelination [14, 15]. 
Causes of chronic demyelinating neuropathy 
 Charcot-Marie-Tooth disease type 1 
 Other forms of Charcot-Marie-Tooth disease 
 Hereditary liability to pressure palsies 
 Other genetic causes - for example, Refsum's disease, 
metachromatic leucodystrophy 
 Chronic inflammatory demyelinating polyradiculoneuropathy 
 Multifocal motor neuropathy 
 Paraproteinaemic demyelinating neuropathy: 
 Associated with monoclonal gammopathy of undetermined 
significance 
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 Associated with solitary myeloma 
Chronic inflammatory demyelinating 
polyradiculoneuropathy is diagnosed from neurophysiological 
testing that shows multifocal abnormalities with partial conduction 
block. This causes the compound muscle action potential following 
proximal stimulation to be smaller than that following distal 
stimulation. Distal and proximal stimulation is given to a nerve of 
abductor pollicis brevis muscle. The upper trace of each pair shows 
the record for distal stimulation. 
 
Fig. 1: Muscle Action Potentials 
 
A. Normal nerve:  
Distal motor latency is short 
and nerve conduction 
velocity rapid (>50m/sec) 
 
B. Demyelinating Neuropathy: 
The distal motor latency is 
prolonged and nerve 
conduction velocity slowed to 
less than 80% of normal. 
 
C. Axonal Neuropathy: 
The action potential is 
reduced, but the distal motor 
latency and nerve conduction 
velocity are unaffected. 
Chronic axonal neuropathy: 
Sensory or sensory and motor axonal polyneuropathy has 
many causes and can be suggested by the history or examination. 
The third stage investigations may indicate less common general 
medical disorders also it is useful to identify cases of diabetes 
mellitus that were not detected by the fasting blood glucose test [16]. 
Chronic idiopathic axonal neuropathy in 25% of elderly 
patients cases may not clearly identified after exhaustive 
investigation. This type of neuropathy is often indolent, 
predominantly sensory, and length dependent. Disease will slowly 
progress without causing serious disabilities [17]. 
Prominent symptoms of axonal neuropathy are loss of 
pain and temperature sensation and spontaneous neuropathic pain, 
described as burning or pricking occur due to degeneration of thinly 
myelinated and unmyelinated nerve fibres. Sometimes small fibre 
neuropathy occurs without affecting the thicker myelinated nerve 
fibres in such cases nerve conduction test results remain normal. 
The diagnosis depends on clinical symptoms and signs which can be 
justified with skin biopsy or enumeration of unmyelinated nerve 
fibres in electron micrographs of a nerve biopsy specimen. The 
diagnosis in some conditions is suggested by other neurological and 
systemic features for chronic axonal neuropathy in patients with 
many multisystem hereditary disorders. The axonal form of 
Charcot-Marie-Tooth disease (type 2) hereditary neuropathy is 
considered as difficult to diagnose, the symptoms of disease usually 
begin in childhood and are associated with pes cavus and claw toes 
but may not come to attention until middle or old age [18-20]. 
Stage 3 investigation: 
 Urine: Bence-Jones protein 
 Biochemistry: Oral glucose tolerance test 
 Cerebrospinal fluid: Cells, protein, immunoglobulin oligoclonal 
bands 
 Immunology: Anti-HIV antibodies, antineuronal antibodies 
(Hu, Yo), antigliadin antibodies, serum angiotensin converting 
enzyme, antiganglioside antibodies, antimyelin associated 
glycoprotein antibodies. 
 Tests for Sjögren's syndrome: Salivary flow rate, Schirmer's 
test, Rose Bengal test, labial gland biopsy. 
 Search for carcinoma, lymphoma, or solitary myeloma: Skeletal 
survey, pelvic ultrasonography, abdominal and chest computed 
tomography, mammography, or positron emission 
tomography. 
 Molecular genetic tests: Peripheral nerve myelin protein 22 
gene duplication (the commonest cause of 
Charcot-Marie-Tooth disease type 1) or deletion (hereditary 
neuropathy with liability to pressure palsies), connexin 32 
mutation (X linked Charcot-Marie-Tooth disease), PO gene 
mutation (another cause of Charcot-Marie-Tooth disease type 
1), etc 
TREATMENT: 
Pain is an important symptom of neuropathy and patients 
usually complain of discomforts like burning or tingling that go 
along with having numbness, any underlying medical cause like 
diabetes mellitus or vitamin B-12 deficiency should be treated first. 
Medications that are specialized for managing nerve pain are often 
used the NSAIDs nonsteroidal anti-inflammatory drugs can relieve 
mild symptoms; most useful drugs are anticonvulsants, especially 
pregabalin, gabapentin, carbamazepine and tricyclic 
antidepressants, especially amitriptyline. Severe cases may require 
stronger narcotic medications like the opioid analgesics. Chronic 
inflammatory demyelinating polyradiculo neuropathy is important 
to recognize and diagnose because it is treatable. The cheapest 
treatment corticosteroids are usually used initially, but the 
condition can also be treated with intravenous immunoglobulin 
(high levels of proteins that work as antibodies), plasma exchange 
(removing antibodies and other proteins from the blood), and some 
immunosuppressant drugs. The uncommon variant, multifocal 
motor neuropathy, responds to intravenous immunoglobulin and 
possibly immunosuppressant drugs but not to corticosteroids or 
plasma exchange. Unfortunately, no specific treatment is available 
for chronic idiopathic axonal polyneuropathy. Neuropathic pain is 
usually treated by pain medications having limited effect and/or 
dose-related side effects when given alone therefore combinations 
of more than one drug are often used with the goal of achieving 
better pain relief or less side effects [21]. 
 
Table No. 4: Medications for Neuropathic Pain 
Medication Dosage 
Pregabalin 100-300 mg every night or 100-300 mg 3 times daily 
Gabapentin 100-300 mg every night or 100-300 mg 3 times daily 
Tricyclic antidepressants 
Eg: nortriptyline or desipramine 
10-25 mg every night 
NSAIDs Eg Ibuprofen combination with 
Pregabalin and/or Gabapentin 
200-400 mg every 4 to 6 hours as needed 
Serotonin-noradrenaline reuptake 
inhibitors 
Eg: duloxetine  and venlafaxine 
60–120 mg, once a day, 150–225 mg, once a day extended release  
Tramadol hydrochloride 50 mg once or twice daily 
Opioid Analgesics 
Eg: morphine sulfate 
5-15 mg every 4 hours as needed 
5% Lidocaine Patchs Maximum of 3 patches daily for a maximum of 12 hr 
8% Capsaicin Patches One to four patches to the painful area for 30-60 min every 3 months 
Botulinum Toxin A (subcutaneously) 50–200 units to the painful area every 3 months 
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MANAGEMENT: 
Painful neuropathy is difficult to treat because patients 
may experience pain, which can be severe and out of proportion to 
any sensory or motor deficit therefore various therapies and 
procedures can be utilized to help ease the signs and symptoms of 
peripheral neuropathy. Preventive and palliative treatments include 
foot care, weight reduction, and sensible shoes, boots, or ankle foot 
orthoses. Physical therapy for muscle weakness can helps to 
improve movements, patients with severe leg weakness may need 
sticks, crutches, or a walking frame or a wheelchair, and wrist 
splints can help weak wrist extension and complex splints for weak 
fingers and hands are usually provided by the physiotherapists. 
Disabled patients may be advised special utensils and home 
adaptations, they require help from a multidisciplinary team by the 
including an occupational therapist. Some drugs like Sildenafil may 
be used to correct erectile impotence. Transcutaneous electrical 
nerve stimulation (TENS) applied for 30 minutes daily for about a 
month by placing adhesive electrodes on the skin which delivers a 
gentle electric current at varying frequencies provides relief from 
neuropathic pain [21]. 
CONCLUSION 
Neuropathies can be sensory, motor or autonomic 
depending on symptoms presents in the type of nerve and the 
location. Sensory nerves tell us how things feel where as motor 
nerves stimulate muscle contraction and initiate movement and 
autonomic nerves control functions that our body unconsciously 
regulates, such as breathing and heart rate. Epidemiological surveys 
around the globe suggest that many patients with neuropathic pain 
do not receive appropriate treatment; the reasons might be low 
diagnostic accuracy insufficient knowledge about the nerve disease, 
effective drugs and their appropriate use in clinical practice. 
Management of the nerve disease and pharmacotherapy of 
neuropathic pain are therefore essential. Current drugs as 
monotherapy are associated with limited efficacy and dose related 
side effects where as combining two or more different drugs may 
improve analgesic efficacy and reduce overall side effects. 
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